Market Overview - On June 19, the Hang Seng Index fell by 1.99%, with southbound trading totaling HKD 118.86 billion, comprising HKD 60.14 billion in buying and HKD 58.72 billion in selling, resulting in a net buying amount of HKD 1.43 billion [1][2] Southbound Trading Details - Southbound trading through the Stock Connect (Shenzhen) recorded a total transaction amount of HKD 41.41 billion, with buying at HKD 20.88 billion and selling at HKD 20.52 billion, leading to a net buying of HKD 0.36 billion [1] - Southbound trading through the Stock Connect (Shanghai) had a total transaction amount of HKD 77.45 billion, with buying at HKD 39.26 billion and selling at HKD 38.19 billion, resulting in a net buying of HKD 1.07 billion [1] Active Stocks - The most actively traded stock by southbound funds was Pop Mart, with a total transaction amount of HKD 54.94 billion, followed by Meituan-W at HKD 53.55 billion and Tencent Holdings at HKD 49.75 billion [1][2] - Among the net buying stocks, Xiaomi Group-W led with a net buying amount of HKD 4.96 billion, despite a closing price drop of 1.39% [1][2] - China Construction Bank had a net buying of HKD 3.70 billion, while ZhongAn Online saw a net buying of HKD 2.78 billion [1] Net Selling Stocks - Tencent Holdings experienced the highest net selling amount of HKD 13.09 billion, with a closing price decline of 1.97% [1][2] - Pop Mart and Alibaba-W faced net selling amounts of HKD 8.35 billion and HKD 2.06 billion, respectively [1][2] Continuous Net Buying - China Construction Bank was noted for having continuous net buying for 7 days, with a total net buying amount of HKD 4.32 billion during this period [2]

Core Insights - On June 19, 2025, Meituan-W (03690), Pop Mart (09992), and China Construction Bank (00939) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 3.409 billion, 3.362 billion, and 3.048 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Pop Mart (09992), Tencent Holdings (00700), and Meituan-W (03690) led the trading volume, with amounts of 2.132 billion, 2.099 billion, and 1.946 billion respectively [1] Southbound Stock Connect - Top Active Companies - Meituan-W (03690) had a trading amount of 3.409 billion with a net buy of -431 million [2] - Pop Mart (09992) recorded a trading amount of 3.362 billion with a net buy of -291 million [2] - China Construction Bank (00939) achieved a trading amount of 3.048 billion with a net buy of +370 million [2] - Tencent Holdings (00700) had a trading amount of 2.876 billion with a net buy of -723 million [2] - Alibaba-W (09988) had a trading amount of 2.112 billion with a net buy of +51 million [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Pop Mart (09992) led with a trading amount of 2.132 billion and a net buy of -544 million [2] - Tencent Holdings (00700) followed with a trading amount of 2.099 billion and a net buy of -586 million [2] - Meituan-W (03690) had a trading amount of 1.946 billion with a net buy of +313 million [2] - Alibaba-W (09988) recorded a trading amount of 1.348 billion with a net buy of -257 million [2] - Xiamen International Bank (01801) had a trading amount of 1.109 billion with a net buy of +35 million [2]

15 June 2025 | 1:53PM HKT Potential opportunities on other technology platforms: Referring to technology platform-based collaborations between China pharma / biotech and MNCs (see summary in Exhibit 1), the upfront payment of US$110mn for the announced AZ/CSPC collaboration is consistent with the historical range of US$10mn to below US$200mn, while the total deal size of US$5.3bn was the highest since 2023. With the current collaboration announced to date, we see growing recognition from MNCs for CSPC's tec ...

Group 1 - The Hong Kong stock market for innovative drug concept stocks continues to decline, with notable drops in several companies [1] - Zai Lab (09688.HK) and Innovent Biologics (02096.HK) both fell over 7% [1] - Other companies such as Luye Pharma (02186.HK) and Genscript Biotech (01952.HK) experienced declines of over 6%, while CSPC Pharmaceutical Group (01093.HK) dropped by 5.9% [1]

Group 1 - The Hang Seng Index in Hong Kong has dropped over 2% [1] - CSPC Pharmaceutical Group has seen a decline of nearly 6% [1] - Zhongsheng Holdings, China Hongqiao Group, and Alibaba Health have all decreased by nearly 5% [1]

恒指跌1%，恒生科技指数跌0.9%，创新药股走低，石药集团(01093.HK)跌3.6%。 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$10.59, representing a potential upside of 20% from the current price of HK$8.84 [1][8][18]. Core Insights - The company has faced revenue declines in its core pharmaceutical business but has offset some of this through strong licensing income, demonstrating its ability to commercialize its pipeline effectively [6][15]. - The report highlights a strategic partnership with AstraZeneca, which includes an upfront payment of US$110 million, indicating strong collaboration in innovative drug development [6][15]. - Adjustments to earnings per share (EPS) forecasts reflect a cautious outlook on the growth of the company's core generic drug business, with 2025 and 2026 EPS estimates reduced by 14% [2][11]. Financial Performance - The company reported a revenue of RMB 70.15 billion in Q1 2025, a year-on-year decline of 21.9%, while net profit was RMB 14.95 billion, down 8.3% [6][10]. - The revenue forecast for 2025 has been adjusted down to RMB 28.306 billion, a decrease of 12% from previous estimates, with a further decline expected in 2026 [12][15]. - The report anticipates a gross margin of 70% for 2025, slightly lower than previous forecasts, reflecting ongoing challenges in the market [11][12]. Research and Development - The company continues to invest in R&D, with expenditures reaching RMB 13 billion in Q1 2025, representing an 11.4% increase year-on-year [7][11]. - The R&D intensity remains high at 23.7% of revenue, indicating a strong commitment to innovation [7][11]. - The company has nearly 90 products in various stages of clinical development, with several already submitted for registration, enhancing future approval efficiency [7][11]. Valuation - The report employs a two-stage DCF model for valuation, adjusting the WACC to 8.5% and increasing the perpetual growth rate to 4% [8][17]. - The target price of HK$10.59 is based on the DCF analysis, suggesting that the current valuation does not fully reflect the company's growth potential in innovative drugs and licensing income [8][17]. - The company's projected P/E ratio for 2025 is 21, slightly above the industry average of 20, indicating a potential undervaluation relative to its peers [8][17].

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, with a total net purchase of HKD 63.02 billion on June 17, 2023, indicating strong investor interest in certain stocks while others faced net sell-offs [1]. Group 1: Northbound Trading Activity - Northbound trading through Stock Connect saw a net purchase of HKD 35.8 billion from Shanghai and HKD 27.22 billion from Shenzhen [1]. - The most purchased stocks included China Construction Bank (00939), Alibaba-W (09988), and Pop Mart (09992) [1]. - The most sold stocks were Tencent (00700), CSPC Pharmaceutical Group (01093), and CNOOC (00883) [1]. Group 2: Individual Stock Performance - China Construction Bank (00939) received a net inflow of HKD 11.21 billion, supported by a report from Changjiang Securities highlighting the bank's dividend value and low valuation compared to H-shares [5]. - Alibaba-W (09988) and Meituan-W (03690) saw net purchases of HKD 5.99 billion and HKD 2.22 billion, respectively, while Tencent (00700) faced a net sell-off of HKD 7.13 billion [5]. - Pop Mart (09992) gained a net inflow of HKD 2.71 billion, with Citigroup noting the company's strong IP recognition and product development capabilities [6]. - Nanjing Panda Electronics (00553) received a net inflow of HKD 1.65 billion, linked to its involvement in brain-computer interface technology [6]. - ZhongAn Online (06060) saw a net inflow of HKD 1.3 billion, with developments in the digital asset space and its partnership with ZA Bank [7]. - Xiaomi Group-W (01810) had a net inflow of HKD 2.2 billion, while SMIC (00981) and CNOOC (00883) faced net sell-offs of HKD 59.9 million and HKD 80.88 million, respectively [8].

Group 1 - The Hong Kong innovative drug sector experienced a significant decline in the afternoon, with Sihuan Pharmaceutical falling nearly 12% and CSPC Pharmaceutical Group dropping over 6% [1]

港股创新药板块午后持续下挫，先声药业(02096.HK)跌近12%，盘初一度涨超6%，绿叶制药(02186.HK) 跌近11%，再鼎医药(09688.HK)跌超7%，石药集团(01093.HK)跌超6%。 ...